New Horizon Health (HKSE:06606) Research & Development: HK$142 Mil (TTM As of Jun. 2023)


HKSE:06606 New Horizon Health Ltd HKSE:06606
35 GF Score
Price HK$14.14
View Full Analysis

What is New Horizon Health Research & Development?

New Horizon Health HKSE:06606 35 Research & Development is HK$142 Mil as of Jun. 2023. GuruFocus rates HKSE:06606 with a GF Score™ of 35/100.

Research & Development is the aggregate amount of research and development expenses during the year. New Horizon Health's Research & Development for the six months ended in Jun. 2023 was HK$82 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was HK$142 Mil.

New Horizon Health  (HKSE:06606) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

New Horizon Health Research & Development Related Terms

New Horizon Health Research & Development Historical Data

* Premium members only.

The historical data trend for New Horizon Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

New Horizon Health Research & Development Chart

New Horizon Health Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
16.79 29.34 30.03 72.13 105.64

New Horizon Health Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only 25.65 46.12 47.96 59.95 81.76
HKSE:06606
35GF Score
New Horizon Health Ltd HKSE:06606
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

New Horizon Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$142 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$142 Mil mean?
New Horizon Health (HKSE:06606) has a Research & Development of HK$142 Mil as of Jun. 2023. Research and development expense is the total cost for research and development activities. View historical data on New Horizon Health and its competitors.
Is New Horizon Health's Research & Development too high?
New Horizon Health's current Research & Development is HK$142 Mil. Overall, New Horizon Health has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does New Horizon Health's Research & Development compare to ABT and SYK?
New Horizon Health's Research & Development of HK$142 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on New Horizon Health and its competitors. New Horizon Health's current Research & Development is HK$142 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Horizon Health stock overvalued right now?
New Horizon Health (HKSE:06606) has a current Research & Development of HK$142 Mil. The current Research & Development is HK$142 Mil. New Horizon Health's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For New Horizon Health (HKSE:06606), the current Research & Development is HK$142 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

New Horizon Health Business Description

Address 400 Jiang’er Road, 13th Floor, T1 Building, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
35GF Score

Get the complete analysis for HKSE:06606

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$14.14
Price